David Cruikshank is a Partner at ARCH Venture Partners where he focuses on instrumentation, biotechnology, diagnostics, semiconductors, nanotechnology, advanced materials, and information technologies. Mr. Cruikshank is a Director to Omniome, Encodia, and Nanosys and an Observer to Arbor Biotechnologies, Genturi, Ultivue, Voxel8, Cytrellis Biosystems, 908 Devices, Boreal Genomics and Agrivida. He previously led ARCH’s investment in Twist Bioscience (TWST).
Mr. Cruikshank holds an M.B.A. with Honors from the University of Chicago, an M.S. in Industrial Engineering and Operations Research from University of California, Berkeley, and a B.S. in Mechanical Engineering from the University of California, Los Angeles.
David is attending / has attended:
The 2018 New England Venture Summit
Venture Summit | West 2020